A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin
versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.